Sodium stibogluconate interacts with IL-2 in anti-renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages

Journal of Immunology

Volumn 175, Issue 10, 2005, Pages 7003-7008

  Fan, Keke ^a   Zhou, Ming ^a   Pathak, Manas K ^a   Lindner, Daniel J ^b   Altuntas, Cengiz Z ^a   Tuohy, Vincent K ^a   Borden, Ernest C ^a,b   Yi, Taolin ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; PROTEIN TYROSINE PHOSPHATASE; SRC HOMOLOGY 2 DOMAIN CONTAINING PHOSPHATASE 1; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER MODEL; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IN VITRO STUDY; INTERFERON PRODUCTION; KIDNEY CARCINOMA; MACROPHAGE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 27744562580     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.10.7003     Document Type: Article

References (36)

1. Greenlee, R. T., M. B. Hill-Harmon, T. Murray, and M. Thun. 2001. Cancer statistics, 2001. CA Cancer J. Clin. 51: 15-36.
2. Mulders, P., R. Figlin, J. B. deKernion, R. Wiltrout, M. Linehan, D. Parkinson, W. deWolf, and A. Belldegrun. 1997. Renal cell carcinoma: recent progress and future directions. Cancer Res. 57: 5189-5195.
3. Motzer, R. J., and P. Russo. 2000. Systemic therapy for renal cell carcinoma. J. Urol. 163: 408-417.
4. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
5. Bukowski, R. M. 1997. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198-1220.
6. Bleumer, I., E. Oosterwijk, P. De Mulder, and P. F. Mulders. 2003. Immunotherapy for renal cell carcinoma. Eur. Urol. 44: 65-75.
7. Rosenberg, S. A. 2000. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 2000: S2-S7.
8. Ellery, J. M., S. J. Kempshall, and P. J. Nicholls. 2000. Activation of the interleukin 2 receptor: a possible role for tyrosine phosphatases. Cell. Signal. 12: 367-373.
9. Pathak, M. K., and T. Yi. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167: 3391-3397.
10. Yi, T., M. K. Pathak, D. J. Lindner, M. E. Ketterer, C. Farver, and E. C. Borden. 2002. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169: 5978-5985.
11. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10: 560-586.
12. Zhang, J., A. K. Somani, and K. A. Siminovitch. 1999. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 12: 361-378.
13. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection: experimental visceral leishmaniasis. J. Clin. Invest. 83: 1253-1257.
14. Murray, H. W., and S. Delph-Etienne. 2000. Roles of endogenous γ interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68: 288-293.
15. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30: 2935-2943.
16. Berman, J. D., and D. J. Wyler. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142: 83-86.
17. Forget, G., K. A. Siminovitch, S. Brochu, S. Rivest, D. Radzioch, and M. Olivier. 2001. Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis. Eur. J. Immunol. 31: 3185-3196.
18. Blanchette, J., N. Racette, R. Faure, K. A. Siminovitch, and M. Olivier. 1999. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-γ-triggered JAK2 activation. Eur. J. Immunol. 29: 3737-3744.
19. Nandan, D., T. Yi, M. Lopez, C. Lai, and N. E. Reiner. 2002. Leishmania EF-1α activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J. Biol. Chem. 277: 50190-50197.
20. Murphy, G. P., and W. J. Hrushesky. 1973. A murine renal cell carcinoma. J. Natl. Cancer Inst. 50: 1013-1025.
21. Gillis, S., and J. Watson. 1980. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J. Exp. Med. 152: 1709-1719.
22. Forsberg, K., I. Valyi-Nagy, C. H. Heldin, M. Herlyn, and B. Westermark. 1993. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA 90: 393-397.
23. Sonouchi, K., T. A. Hamilton, C. S. Tannenbaum, R. R. Tubbs, R. Bukowski, and J. H. Finke. 1994. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-α and interleukin-2. Am. J. Pathol. 144: 747-755.
24. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: γ interferon plus pentavalent antimony. J. Infect. Dis. 157: 973-978.
25. Lindner, D. J., E. C. Borden, and D. V. Kalvakolanu. 1997. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res. 3: 931-937.
26. Joliat, M. J., P. A. Lang, B. L. Lyons, L. Burzenski, M. A. Lynes, T. Yi, J. P. Sundberg, and L. D. Shultz. 2002. Absence of CD5 dramatically reduces progression of pulmonary inflammatory lesions in SHP-1 protein-tyrosine phosphatase-deficient 'viable motheaten' mice. J. Autoimmun. 18: 105-117.
27. + tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res. 50: 2363-2370.
28. Margolin, K. A. 2000. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27: 194-203.
29. Samlowski, W. E., R. Petersen, S. Cuzzocrea, H. Macarthur, D. Burton, J. R. McGregor, and D. Salvemini. 2003. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat. Med. 9: 750-755.
30. Klimp, A. H., E. G. de Vries, G. L. Scherphof, and T. Daemen. 2002. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 44: 143-161.
31. + T cells. Cancer Res. 63: 4095-4100.
32. Green, M. C., and L. D. Shultz. 1975. Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology. J. Hered. 66: 250-258.
33. Shultz, L. D., D. R. Coman, C. L. Bailey, W. G. Beamer, and C. L. Sidman. 1984. "Viable motheaten," a new allele at the motheaten locus. 1. Pathology. Am. J. Pathol. 116: 179-192.
34. Shultz, L. D., P. A. Schweitzer, T. V. Rajan, T. Yi, J. N. Ihle, R. J. Matthews, M. L. Thomas, and D. R. Beier. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73: 1445-1454.
35. Masztalerz, A., N. Van Rooijen, W. Den Otter, and L. A. Everse. 2003. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol. Immunother. 52: 235-242.
36. Espinoza-Delgado, I., M. C. Bosco, T. Musso, G. L. Gusella, D. L. Longo, and L. Varesio. 1995. Interleukin-2 and human monocyte activation. J. Leukocyte Biol. 57: 13-19.